Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 401–500 of 1,003
Lai, M.-J., Ojha, R., Lin, M.-H., Liu, Y.-M., Lee, H., Lin, T. E., Hsu, K., Chang, C.-Y., Chen, M.-C., Nepali, K., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.066 · Cited by 49
Novel Therapies for Relapsed and Refractory Neuroblastoma
Zage, P. E. (2018) · Children · doi:10.3390/children5110148 · Cited by 56
“The epigenomic landscape has been shown to contribute to neuroblastoma pathogenesis, leading to early phase clinical trials investigating the safety and efficacy of epigenetic agents [85–87], including drugs that target epigenetic writers, such as DNA methyltransferases, as well as epigenetic erasers, such as histone…”
BackgroundHuman Trophoblast Differentiation Is Associated With Profound Gene Regulatory and Epigenetic Changes
Kwak, Y.-T., Muralimanoharan, S., Gogate, A. A., & Mendelson, C. R. (2019) · Endocrinology · doi:10.1210/en.2019-00144 · Cited by 52
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 63
Mao, Y., Soni, K. V., Sangani, C. B., & Yao, Y. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620999200917154225 · Cited by 49
Fu, M., Wan, F., Li, Z., & Zhang, F. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.030 · Cited by 50
Histone Deacetylases in Cartilage Homeostasis and Osteoarthritis
Shull, L. C., & Westendorf, J. J. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0602-z · Cited by 48
Acetylation-Dependent Control of Global Poly(A) RNA Degradation by CBP/p300 and HDAC1/2
Sharma, S., Poetz, F., Bruer, M., Ly-Hartig, T. B. N., Schott, J., Séraphin, B., & Stoecklin, G. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.030 · Cited by 54
Gabano, E., Ravera, M., Zanellato, I., Tinello, S., Gallina, A., Rangone, B., Gandin, V., Marzano, C., Bottone, M. G., & Osella, D. (2017) · Dalton Transactions · doi:10.1039/c7dt02928d · Cited by 48
Berry, B. J., Smith, A. S. T., Young, J. E., & Mack, D. L. (2018) · Cells Tissues Organs · doi:10.1159/000493018 · Cited by 49
Ustinova, K., Nováková, Z., Saito, M., Meleshin, M., Mikesova, J., Kutil, Z., Baranová, P., Havlínová, B., Schutkowski, M., Matthias, P., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011243 · Cited by 50
Burke, B., Eden, C., Pérez, C., Belshoff, A. C., Hart, S., Plaza-Rojas, L., Reyes, M. D., Prajapati, K., Voelkel‐Johnson, C., Henry, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00699 · Cited by 47
“and peripheral T cell lymphoma (PTCL) (39), and multiple myeloma (40, 41).”
BackgroundYao, D., Li, C., Jiang, J., Huang, J. M., Wang, J., He, Z., & Zhang, J. C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112648 · Cited by 48
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
Bhat, M. F., Srdanović, S., Sundberg, L.-R., Einarsdottir, H., Marjomäki, V., & Dekker, F. J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104193 · Cited by 49
Blank, M., Enzlein, T., & Hopf, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06894-1 · Cited by 51
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
Cao, H., Li, L., Xue, S., & Dai, H. (2022) · Hematological Oncology · doi:10.1002/hon.3088 · Cited by 49
“and HDAC2, thereby negatively regulating RUNX1 target genes to prevent myeloid differentiation and resulting in cellular transformation.(62,63) The CBFβ:MYH11 fusion gene encodes CBFβ and smooth muscle myosin heavy chain.”
Epigenetics as a versatile regulator of fibrosis
Liu, Y., Wen, D., Ho, C., Li, Y., Zheng, D., O’Reilly, S., Gao, Y., Li, Q., & Zhang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04018-5 · Cited by 55
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 61
“Aberrant expression of HDACs is a well-established pro-cancer factor, and inhibiting HDAC function provides multiple antitumor effects [4, 36].”
Wu, T., Zhao, Y., Zhang, X., Wang, Y., Chen, Q., Zhang, M., Sheng, H., Zhang, Y., Guo, J., Li, J., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70048 · Cited by 60
“Due to their lack of specificity for a particular HDAC isoenzyme, these inhibitors may cause off-target effects such as nausea, vomiting, fatigue, and cardiotoxicity, limiting their clinical use [189].”
Wang, C., Chen, J., Cao, W., Sun, L., Sun, H., & Liu, Y. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.049 · Cited by 47
ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis
Lim, R. R., Tan, A., Liu, Y., Barathi, V. A., Mohan, R. R., Mehta, J. S., & Chaurasia, S. S. (2016) · Scientific Reports · doi:10.1038/srep20841 · Cited by 49
The therapeutic potential of epigenetic manipulation during infectious diseases
Cole, J., Morris, P., Dickman, M. J., & Dockrell, D. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.013 · Cited by 52
Nicholson, J., Jevons, S. J., Grošelj, B., Ellermann, S. F., Konietzny, R., Kerr, M., Kessler, B. M., & Kiltie, A. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3232 · Cited by 51
HDAC4 in ischemic stroke: mechanisms and therapeutic potential
Kong, Q., Hao, Y., Li, X., Wang, X., Ji, B., & Wu, Y. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0549-1 · Cited by 47
“No HDAC-based approach or agent has been approved for ischemic stroke treatment, although four pan-HDAC inhibitors, vorinostat, romidepsin, belinostat, and panobinostat, are approved by the US FDA for the treatment of cutaneous T cell lymphoma, peripheral T cell lymphoma, and multiple myeloma, respectively [86, 87].”
BackgroundGao, Y., Zhang, C., Chang, J., Yang, C., Liu, J., Fan, S., & Ren, C. (2019) · Biomaterials Science · doi:10.1039/c8bm01422a · Cited by 47
Debnath, S., Debnath, T., Bhaumik, S., Majumdar, S., Kalle, A. M., & Vema, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-53376-y · Cited by 52
Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML
Yu, X., Li, H., Hu, P., Qing, Y., Wang, X., Zhu, M., Wang, H., Wang, Z., Xu, J., Guo, Q., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.154 · Cited by 48
Cadet, J. L., & Jayanthi, S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105069 · Cited by 48
Liu, X., Xiang, M., Tong, Z.-X., Luo, F.-Y., Chen, W., Liu, F., Wang, F., Yu, R., & Jiang, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00709 · Cited by 47
Jiang, W., Xia, T., Liu, C., Li, J., Zhang, W., & Sun, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705903 · Cited by 55
“HDAC and HAT can interact with proto-oncogenes and tumor suppressor genes and thereby interfere with the regulation of these genes during tumor cell proliferation, metastasis, and apoptosis (49, 50).”
BackgroundGong, C.-J., Gao, A., Zhang, Y., Su, M., Chen, F., Sheng, L., Zhou, Y., Li, J.-Y., Li, J. X., & Nan, F. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.003 · Cited by 49
Do, A., Reid, R. C., Lohman, R., Sweet, M. J., Fairlie, D. P., & Iyer, A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.236711 · Cited by 51
Rodrigues, D. A., Guerra, F. S., Sagrillo, F. S., Pinheiro, P. D. S. M., Alves, M. A., Thota, S., Chaves, L. D. S., Sant’Anna, C. M. R., Fernandes, P. D., & Fraga, C. A. M. (2020) · ChemMedChem · doi:10.1002/cmdc.201900716 · Cited by 49
An amber obligate active site-directed ligand evolution technique for phage display
Tharp, J. M., Hampton, J. T., Reed, C. A., Ehnbom, A., Chen, P. C., Morse, J. S., Kurra, Y., Pérez, L. M., Xu, S., & Liu, W. R. (2020) · Nature Communications · doi:10.1038/s41467-020-15057-7 · Cited by 47
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2020) · Molecules · doi:10.3390/molecules25194394 · Cited by 45
“Abnormal changes in HDAC expression and therefore the levels of deacetylation have been associated with a range of diseases, including many cancers [8].”
BackgroundLiu, J., Qiu, J., Zhang, Z., Zhou, L., Li, Y., Ding, D., Zhang, Y., Zou, D., Wang, D., Zhou, Q., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00539-y · Cited by 49
“The mechanisms underlying HDAC1-driven cancer development involve in several cellular processes, including cell cycle, apoptosis, DNAdamage response, and autophagy [20].”
BackgroundInfluentialKDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression
Wei, H., Ma, W., Lü, X., Liu, H., Lin, K., Wang, Y., Ye, Z., Sun, L., Huang, Z.-T., Pan, T., et al. (2021) · 癌症:英文版 · doi:10.1002/cac2.12180 · Cited by 46
“The aberrant expression of HDACs has been found in various types of cancers, which makes HDACs potential targets for cancer therapy [4].”
BackgroundGPR43 regulates sodium butyrate-induced angiogenesis and matrix remodeling
Castro, P. R., Bittencourt, L. F. F., Larochelle, S., Andrade, S. P., Mackay, C. R., SLEVIN, M. A., Moulin, V. J., & Barcelos, L. S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00515.2019 · Cited by 46
Pyka, P., Garbo, S., Fioravanti, R., Jacob, C., Hittinger, M., Handzlik, J., Zwergel, C., & Battistelli, C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104062 · Cited by 50
Song, S., Wang, Y., Xu, P., Yang, R., Ma, Z., Liang, S., & Zhang, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3182 · Cited by 48
Zhang, X. M., Cook, P. C., Zindy, E., Williams, C. J., Jowitt, T. A., Streuli, C. H., MacDonald, A. S., & Redondo-Muñóz, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1348 · Cited by 42
Lines, K. E., Stevenson, M., Filippakopoulos, P., Müller, S., Lockstone, H. E., Wright, B., Grozinsky‐Glasberg, S., Grossman, A. B., Knapp, S., Buck, D., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.30 · Cited by 47
Targeting FBPase is an emerging novel approach for cancer therapy
Liu, G., & Zhang, Y.-M. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0533-z · Cited by 50
“However, we are still a long way from the clinical application of these epigenetic drugs for solid tumours [132].”
BackgroundTargeting histone demethylase KDM5B for cancer treatment
Fu, Y.-D., Huang, M.-J., Guo, J., You, Y.-Z., Liu, H., Huang, L., & Yu, B. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112760 · Cited by 48
Polli, A., Ickmans, K., Godderis, L., & Nijs, J. (2018) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2018.09.118 · Cited by 48
The HDAC3 enzymatic activity regulates skeletal muscle fuel metabolism
Song, S., Wen, Y., Tong, H. N., Loro, E., Gong, Y., Liu, J., Hong, S., Li, L., Khurana, T. S., Chu, M., et al. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy066 · Cited by 44
Hsieh, Y.-L., Tu, H., Pan, S., Liou, J., & Yang, C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.03.003 · Cited by 44
Zhang, S., Gong, C.-J., Su, M., Chen, F., He, T., Zhang, Y., Shen, Q., Su, Y., Ding, J., Li, J. X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01792 · Cited by 46
Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis
Schmidt, O., Nehls, N., Prexler, C., von Heyking, K., Groll, T., Pardon, K., García, H. D., Hensel, T., Gürgen, D., Henssen, A. G., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02125-z · Cited by 51
Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy
Dai, W., Zhang, J., Li, S., He, F., Liu, Q., Gong, J., Yang, Z., Gong, Y. Q., Tang, F., Wang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865964 · Cited by 52
“While epigenetic regulators are involved in the activation and translocation of immune cells to the TME, as well as subsequent immune responses, their specific roles in tumor immunity and their combined effects with immunotherapy remain unclear (7, 8).”
BackgroundAdvances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 47
[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease
Pascoal, T. A., Chamoun, M., Lax, E., Wey, H.-Y., Shin, M., Ng, K. P., Kang, M. S., Mathotaarachchi, S., Benedet, A. L., Therriault, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30653-5 · Cited by 43
“We obtained from the Douglas-Bell Canada Brain Bank, with the approval of the Brain Bank’s and Douglas Institute’s ethics boards, frozen brain tissues from the posterior cingulate and prefrontal cortices of six patients (3 males, mean age= 76 (7)) with antemortem and postmortem diagnosis of sporadic AD (Consortium to…”
MethodCardioprotection in ischaemia–reperfusion injury: novel mechanisms and clinical translation
Altamirano, F. J., Wang, Z. V., & Hill, J. A. (2015) · The Journal of Physiology · doi:10.1113/jp270953 · Cited by 46
Wei, T.-T., Lin, Y., Tseng, R.-Y., Shun, C., Lin, Y., Wu, M., Fang, J., & Chen, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2379 · Cited by 43
Diedrich, D., Stenzel, K., Hesping, E., Antonova‐Koch, Y., Gebru, T., Duffy, S., Fisher, G. M., Schöler, A., Meister, S., Kurz, T., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.018 · Cited by 44
Liu, J., Zhou, J., He, F.-J., Gao, L., Wen, Y., Gao, L., Wang, P., Kang, D., & Hu, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112189 · Cited by 43
Kroon, E. D. M. B., Ananworanich, J., Pagliuzza, A., Rhodes, A., Phanuphak, N., Trautmann, L., Mitchell, J. L., Chintanaphol, M., Intasan, J., Pinyakorn, S., et al. (2020) · Journal of Virus Eradication · doi:10.1016/j.jve.2020.100004 · Cited by 47
PROTACs: New method to degrade transcription regulating proteins
Hu, B., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 41
Dai, M., Liu, M., Yang, H., Küçük, C., & You, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00356-0 · Cited by 53
“Some of them affect the acetylation status of non-histone and/or non-nuclear proteins or cause off-target effects like DNA damage, while others clearly cause epigenetic alterations and affect histone acetylation [48, 49].”
BackgroundThe role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Johnson, A. L., Laterra, J., & López-Bertoni, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995498 · Cited by 50
Yang, Y., Zhong, Z., Wang, B., & Wang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113902 · Cited by 46
Mustafa, A. M., & Krämer, O. H. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000612 · Cited by 46
The application of PROTAC in HDAC
Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 46
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia
Zhang, C., Zhong, J. F., Stucky, A., Chen, X., Press, M. F., & Zhang, X. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0151-8 · Cited by 54
Shen, T., Sanchez, H. N., Zan, H., & Casali, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00627 · Cited by 43
Epigenetic regulation of bone cells
Park‐Min, K. H. (2016) · Connective Tissue Research · doi:10.1080/03008207.2016.1177037 · Cited by 45
Wright, L. H., & Menick, D. R. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00271.2016 · Cited by 43
Hakami, N., Dusting, G. J., & Peshavariya, H. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12885 · Cited by 46
Hamada, M., & Yura, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197073 · Cited by 42
“HDAC deregulation has been implicated in the promotion of both carcinogenesis and tumor progression [131], thereby promoting the development of a number of histone deacetylase inhibitors (HDACIs) with wide-ranging anti-cancer properties [132].”
BackgroundHDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer
Clements, M. E., Holtslander, L., Edwards, C. M., Todd, V. M., Dooyema, S. D. R., Bullock, K. K., Bergdorf, K. N., Zahnow, C. A., Connolly, R. M., & Johnson, R. W. (2021) · Oncogene · doi:10.1038/s41388-021-01931-1 · Cited by 45
“Aberrant HDAC expression and activity are frequently observed in cancer and result in enhanced proliferation, angiogenesis, and metastasis [6].”
BackgroundZhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 43
“Conversely, the reversal of histone and non-histone protein acetylation by histone deacetylase (HDAC) inhibitors can induce cell cycle arrest, differentiation, and cancer cell death [18, 19].”
BackgroundRaucci, A., Zwergel, C., Valente, S., & Mai, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01677 · Cited by 46
Meng, J., Liu, X., Zhang, P., Li, D., Xu, S., Zhou, Q., Guo, M., Huai, W., Chen, X., Wang, Q., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.012 · Cited by 42
Tian, Y., Liu, G., Wang, H., Tian, Z., Cai, Z., Zhang, F., Luo, Y. Y., Wang, S., Guo, G., Wang, X., et al. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.08.002 · Cited by 39
Chen, M.-C., Lin, Y., Liao, Y.-H., Liou, J., & Chen, C. (2019) · Cancers · doi:10.3390/cancers11101617 · Cited by 44
“Histone deacetylases (HDACs) are one of the major epigenetic enzymes that function as acetyl group removers of lysine residues from histones or non-histone protein substrates [4].”
BackgroundHii, L., Chung, F. F., Soo, J. S.-S., Tan, B. S., Mai, C., & Leong, C. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05504-5 · Cited by 43
Zn2+-Dependent Histone Deacetylases in Plants: Structure and Evolution
Yruela, I., Moreno–Yruela, C., & Olsen, C. A. (2021) · Trends in Plant Science · doi:10.1016/j.tplants.2020.12.011 · Cited by 40
Wang, Y., Xie, Q., Tan, H., Liao, M., Zhu, S., Zheng, L., Huang, H., & Liu, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105702 · Cited by 44
Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity
Moreno–Yruela, C., & Olsen, C. A. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00702 · Cited by 44
Determination of Slow-binding HDAC Inhibitor Potency and Subclass Selectivity
Moreno-Yruela, C., & Olsen, C. A. (2021) · doi:10.1101/2021.12.18.473277 · Cited by 41
Warda, E. T., El‐Ashmawy, M. B., Habib, E. E., Abdelbaky, M. S. M., García‐Granda, S., Thamotharan, S., & El-Emam, A. A.-R. (2022) · Scientific Reports · doi:10.1038/s41598-022-25390-0 · Cited by 44
Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release
Bockstiegel, J., Wurnig, S. L., Engelhardt, J., Enns, J., Hansen, F. K., & Weindl, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115693 · Cited by 40
Sirtuins as modifiers of Parkinson's disease pathology
Tang, B. L. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23806 · Cited by 40
Ho, Y. K., Zhou, L. H., Tam, K. C., & Too, H. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1143 · Cited by 39
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors
Zhao, C., Zang, J., Ding, Q., Inks, E. S., Xu, W., Chou, C. J., & Zhang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.002 · Cited by 40
Xie, D., Zhu, J., Liu, Q., Li, J., Song, M., Wang, K., Zhou, Q., Jia, Y., & Li, T. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz006 · Cited by 44
Shouksmith, A. E., Shah, F., Grimard, M., Gawel, J. M., Raouf, Y. S., Geletu, M., Berger‐Becvar, A., de Araujo, E. D., Luchman, H. A., Heaton, W. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01957 · Cited by 42
Perla, A., Fratini, L., Cardoso, P. S., Nör, C., Brunetto, A. T., Brunetto, A. L., de Farias, C. B., Jaeger, M. D. C., & Roesler, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00546 · Cited by 47
“Finally, HDAC11 has been proposed as a Class IV HDAC (Falkenberg and Johnstone, 2014; Hassell, 2019; D’Mello, 2020; Milazzo et al., 2020).”
BackgroundWei, M., Xie, M., Zhang, Z., Wei, Y., Zhang, J., Pan, H., Li, B., Wang, J., Song, Y., Chong, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112677 · Cited by 40
Tilekar, K. N., Hess, J. D., Upadhyay, N., Bianco, A. L., Schweipert, M., Laghezza, A., Loiodice, F., Meyer‐Almes, F., Aguilera, R. J., Lavecchia, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00491 · Cited by 41
Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders
Leite, J. A., Ghirotto, B., Targhetta, V. P., de Lima, J., & Câmara, N. O. S. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15570 · Cited by 45
“Several HDAC inhibitors, for example, vorinostat (suberoylanilide hydroxamic acid®) (Falkenberg & Johnstone, 2014) and belinostat (Beleodaq®, PXD-101 or PXD101) (Finn et al., 2016) have been approved mainly for use in malignancies (Eckschlager et al., 2017).”
BackgroundDifferential molecular mechanistic behavior of HDACs in cancer progression
Singh, T., Kaur, P., Singh, P., Singh, S., & Munshi, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01770-4 · Cited by 46
“HDACs have also been reported to be implicated in various diseases including neurodegenerative diseases like Alzheimer’s, Huntington’s and Parkinson’s disease [26], cardiovascular diseases such as cardiac hypertrophy, myocardial infarction, atrial fibrillation [27], immune disorders, and cancer [28].”
BackgroundEpigenetics in Tuberculosis: Immunomodulation of Host Immune Response
Khadela, A. D., Chavda, V. P., Postwala, H. I., Shah, Y. S., Mistry, P., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10101740 · Cited by 47
“As opposed to broad spectrum HDAC inhibitor, tubustatin enhances the macrophage generation of mitochondrial ROS, as a TLR-generated microbicidal response leading to increased intracellular microbial clearance [104,105].”
BackgroundFu, M., Shi, W., Li, Z., & Liu, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.147 · Cited by 41
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition
Krönung, S. K., Beyer, U., Chiaramonte, M. L., Dolfini, D., Mantovani, R., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9255 · Cited by 44
Zhu, X., Liu, X., Cheng, Z., Zhu, J., Xu, L., Wang, F., Qi, W., Yan, J., Liu, N., Sun, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep19926 · Cited by 39
Pham‐The, H., Casañola‐Martín, G. M., Diéguez‐Santana, K., Nguyen-Hai, N., Ngoc, N. T., Vu-Duc, L., & Le‐Thi‐Thu, H. (2017) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2017.1294198 · Cited by 38
Lv, W., Zhang, G., Bařinka, C., Eubanks, J. H., & Kozikowski, A. P. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00012 · Cited by 39
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.